Table of Content

Table of Contents

Global Dendritic Cell Cancer Vaccine Market Segment Research Report 2022
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Dendritic Cell Cancer Vaccine Market by Value
2.2.1 Global Dendritic Cell Cancer Vaccine Revenue by Type
2.2.2 Global Dendritic Cell Cancer Vaccine Market by Value (%)
2.3 Global Dendritic Cell Cancer Vaccine Market by Production
2.3.1 Global Dendritic Cell Cancer Vaccine Production by Type
2.3.2 Global Dendritic Cell Cancer Vaccine Market by Production (%)

3. The Major Driver of Dendritic Cell Cancer Vaccine Industry
3.1 Historical & Forecast Global Dendritic Cell Cancer Vaccine Demand
3.2 Largest Application for Dendritic Cell Cancer Vaccine (2018-2028)
3.3 The Major Downstream Company in China Market 2022

4. Global and Regional Dendritic Cell Cancer Vaccine Market
4.1 Regional Market Size in Terms of Production & Demand (2022)
4.2 Regional Market Share in Terms of Revenue (2018-2022)
4.3 Concentration Ratio (CR5& CR10) of Dendritic Cell Cancer Vaccine Market
4.4 Mergers & Acquisitions, Expansion Plans

5. US Dendritic Cell Cancer Vaccine Production, Revenue (2018-2028)
5.1 Current and Estimated Production Breakdown by Type
5.2 Current and Estimated Production Breakdown by Application
5.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
5.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

6. Europe Dendritic Cell Cancer Vaccine Production, Revenue (2018-2028)
6.1 Current and Estimated Production Breakdown by Type
6.2 Current and Estimated Production Breakdown by Application
6.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
6.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

7. China Dendritic Cell Cancer Vaccine Production, Revenue (2018-2028)
7.1 Current and Estimated Production Breakdown by Type
7.2 Current and Estimated Production Breakdown by Application
7.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
7.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

8. Japan Dendritic Cell Cancer Vaccine Production, Revenue (2018-2028)
8.1 Current and Estimated Production Breakdown by Type
8.2 Current and Estimated Production Breakdown by Application
8.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
8.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

9. India Dendritic Cell Cancer Vaccine Production, Revenue (2018-2028)
9.1 Current and Estimated Production Breakdown by Type
9.2 Current and Estimated Production Breakdown by Application
9.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
9.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

10. Korea Dendritic Cell Cancer Vaccine Production, Revenue (2018-2028)
10.1 Current and Estimated Production Breakdown by Type
10.2 Current and Estimated Production Breakdown by Application
10.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
10.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

11. Southeast Asia Dendritic Cell Cancer Vaccine Production, Revenue (2018-2028)
11.1 Current and Estimated Production Breakdown by Type
11.2 Current and Estimated Production Breakdown by Application
11.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
11.4 Current and Estimated Revenue Breakdown by Application (2018-2028)

12. Global Dendritic Cell Cancer Vaccine Average Price Trend
12.1 Market Price for Each Type of Dendritic Cell Cancer Vaccine in US (2018-2022)
12.2 Market Price for Each Type of Dendritic Cell Cancer Vaccine in Europe (2018-2022)
12.3 Market Price for Each Type of Dendritic Cell Cancer Vaccine in China (2018-2022)
12.4 Market Price for Each Type of Dendritic Cell Cancer Vaccine in Japan (2018-2022)
12.5 Market Price for Each Type of Dendritic Cell Cancer Vaccine in India (2018-2022)
12.6 Market Price for Each Type of Dendritic Cell Cancer Vaccine in Korea (2018-2022)
12.7 Market Price for Each Type of Dendritic Cell Cancer Vaccine in Southeast Asia (2018-2022)

13. Industrial Chain (Impact of COVID-19)
13.1 Dendritic Cell Cancer Vaccine Industrial Chain Analysis
13.2 Downstream
13.3 Impact of COVID-19
13.4 Post-pandemic Era
13.5 Technology Trends of Dendritic Cell Cancer Vaccine

14. Dendritic Cell Cancer Vaccine Competitive Landscape
14.1 Medigene
14.1.1 Medigene Company Profiles
14.1.2 Medigene Product Introduction
14.1.3 Medigene Dendritic Cell Cancer Vaccine Production, Revenue (2018-2022)
14.1.4 Strategic initiatives
14.2 Activarti
14.2.1 Activarti Company Profiles
14.2.2 Activarti Product Introduction
14.2.3 Activarti Dendritic Cell Cancer Vaccine Production, Revenue (2018-2022)
14.2.4 Strategic initiatives
14.3 Argos Therapeutics
14.3.1 Argos Therapeutics Company Profiles
14.3.2 Argos Therapeutics Product Introduction
14.3.3 Argos Therapeutics Dendritic Cell Cancer Vaccine Production, Revenue (2018-2022)
14.3.4 Strategic initiatives
14.4 Batavia Bioservices
14.4.1 Batavia Bioservices Company Profiles
14.4.2 Batavia Bioservices Product Introduction
14.4.3 Batavia Bioservices Dendritic Cell Cancer Vaccine Production, Revenue (2018-2022)
14.4.4 Strategic initiatives
14.5 Bellicum Pharmaceuticals
14.5.1 Bellicum Pharmaceuticals Company Profiles
14.5.2 Bellicum Pharmaceuticals Product Introduction
14.5.3 Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccine Production, Revenue (2018-2022)
14.5.4 Strategic initiatives
14.6 Creagene
14.6.1 Creagene Company Profiles
14.6.2 Creagene Product Introduction
14.6.3 Creagene Dendritic Cell Cancer Vaccine Production, Revenue (2018-2022)
14.6.4 Strategic initiatives
14.7 DanDrit Biotech
14.7.1 DanDrit Biotech Company Profiles
14.7.2 DanDrit Biotech Product Introduction
14.7.3 DanDrit Biotech Dendritic Cell Cancer Vaccine Production, Revenue (2018-2022)
14.7.4 Strategic initiatives
14.8 DCPrime
14.8.1 DCPrime Company Profiles
14.8.2 DCPrime Product Introduction
14.8.3 DCPrime Dendritic Cell Cancer Vaccine Production, Revenue (2018-2022)
14.8.4 Strategic initiatives
14.9 Sanpower Corporation (Dendreon)
14.9.1 Sanpower Corporation (Dendreon) Company Profiles
14.9.2 Sanpower Corporation (Dendreon) Product Introduction
14.9.3 Sanpower Corporation (Dendreon) Dendritic Cell Cancer Vaccine Production, Revenue (2018-2022)
14.9.4 Strategic initiatives
14.10 Elios Therapeutics
14.10.1 Elios Therapeutics Company Profiles
14.10.2 Elios Therapeutics Product Introduction
14.10.3 Elios Therapeutics Dendritic Cell Cancer Vaccine Production, Revenue (2018-2022)
14.10.4 Strategic initiatives
14.11 Immunicum
14.12 Kiromic
14.13 Merck
14.14 Northwest Biotherapeutics
14.15 Glaxo Smith Kline
14.16 ImmunoCellular
14.17 Tella
14.18 Vaxil Bio
14.19 Medigene
15. Conclusion
16. Methodology and Data Source

List of Figure

List of Tables and Figures

Figure 1. Total Demand by Application of Dendritic Cell Cancer Vaccine Industry (Volume)
Figure 2. Dendritic Cell Cancer Vaccine Production & Demand by Regions in 2022
Figure 3. Regional Market Share in Terms of Revenue (2022&2027)
Figure 4. The Top 10 and 5 Players Market Share by Dendritic Cell Cancer Vaccine Revenue in 2022
Figure 5. US Dendritic Cell Cancer Vaccine Production, Demand (2018-2028)
Figure 6. Production Breakdown by Type (%)
Figure 7. Demand Breakdown by Type (%)
Figure 8. Demand Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Dendritic Cell Cancer Vaccine Production, Demand (2018-2028)
Figure 12. Production Breakdown by Type (%)
Figure 13. Demand Breakdown by Type (%)
Figure 14. Demand Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Dendritic Cell Cancer Vaccine Production, Demand (2018-2028)
Figure 18. Production Breakdown by Type (%)
Figure 19. Demand Breakdown by Type (%)
Figure 20. Demand Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Dendritic Cell Cancer Vaccine Production, Demand (2018-2028)
Figure 25. Production Breakdown by Type (%)
Figure 26. Demand Breakdown by Type (%)
Figure 27. Demand Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Dendritic Cell Cancer Vaccine Production, Demand (2018-2028)
Figure 31. Production Breakdown by Type (%)
Figure 32. Demand Breakdown by Type (%)
Figure 33. Demand Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Dendritic Cell Cancer Vaccine Production, Demand (2018-2028)
Figure 37. Production Breakdown by Type (%)
Figure 38. Demand Breakdown by Type (%)
Figure 39. Demand Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Dendritic Cell Cancer Vaccine Production, Demand (2018-2028)
Figure 43. Current and Estimated Production Breakdown by Type (2018-2028)
Figure 44. Production Breakdown by Type (%)
Figure 45. Demand Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Dendritic Cell Cancer Vaccine Revenue, by Type (Million USD) (2018-2028)
Table 4. Dendritic Cell Cancer Vaccine Production, by Type (K Unit) (2018-2028)
Table 5. Dendritic Cell Cancer Vaccine Demand (K Unit) by Application (2018-2028)
Table 6. Dendritic Cell Cancer Vaccine Demand (Million USD) by Application (2018-2028)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Production & Demand (2022)
Table 9. Regional Market Share in Terms of Revenue (2022&2027)
Table 10. Ranking of Global Top Dendritic Cell Cancer Vaccine Companies by Revenue, Concentration Ratio in 2022
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Dendritic Cell Cancer Vaccine Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 13. Current and Estimated Production Breakdown by Type (2018-2028)
Table 14. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 15. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Dendritic Cell Cancer Vaccine Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 19. Current and Estimated Production Breakdown by Type (2018-2028)
Table 20. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 21. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Dendritic Cell Cancer Vaccine Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 25. Table Current and Estimated Production Breakdown by Type
Table 26. Current and Estimated Demand Breakdown by Type
Table 27. Current and Estimated Demand Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Dendritic Cell Cancer Vaccine Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 30. Current and Estimated Production Breakdown by Type (2018-2028)
Table 31. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 32. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Dendritic Cell Cancer Vaccine Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 36. Current and Estimated Production Breakdown by Type (2018-2028)
Table 37. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 38. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Dendritic Cell Cancer Vaccine Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 42. Current and Estimated Production Breakdown by Type (2018-2028)
Table 43. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 44. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Dendritic Cell Cancer Vaccine Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 48. Table Current and Estimated Demand Breakdown by Type (2018-2028)
Table 49. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Dendritic Cell Cancer Vaccine in US (2018-2022)
Table 53. Market Price (USD/Unit) for Each Type of Dendritic Cell Cancer Vaccine in Europe (2018-2022)
Table 54. Market Price (USD/Unit) for Each Type of Dendritic Cell Cancer Vaccine in China (2018-2022)
Table 55. Market Price (USD/Unit) for Each Type of Dendritic Cell Cancer Vaccine in Japan (2018-2022)
Table 56. Market Price (USD/Unit) for Each Type of Dendritic Cell Cancer Vaccine in India (2018-2022)
Table 57. Market Price (USD/Unit) for Each Type of Dendritic Cell Cancer Vaccine in Korea (2018-2022)
Table 58. Market Price (USD/Unit) for Each Type of Dendritic Cell Cancer Vaccine in Southeast Asia (2018-2022)
Table 59. Key Downstream Customer in Each Application Field
Table 60. Medigene Profiles
Table 61. Medigene Dendritic Cell Cancer Vaccine Product Introduction
Table 62. Medigene Dendritic Cell Cancer Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 63. Medigene Strategic initiatives
Table 64. Activarti Profiles
Table 65. Activarti Dendritic Cell Cancer Vaccine Product Introduction
Table 66. Activarti Dendritic Cell Cancer Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 67. Activarti Strategic initiatives
Table 68. Argos Therapeutics Profiles
Table 69. Argos Therapeutics Dendritic Cell Cancer Vaccine Product Introduction
Table 70. Argos Therapeutics Dendritic Cell Cancer Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 71. Argos Therapeutics Strategic initiatives
Table 72. Batavia Bioservices Profiles
Table 73. Batavia Bioservices Dendritic Cell Cancer Vaccine Product Introduction
Table 74. Batavia Bioservices Dendritic Cell Cancer Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 75. Batavia Bioservices Strategic initiatives
Table 76. Bellicum Pharmaceuticals Profiles
Table 77. Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccine Product Introduction
Table 78. Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 79. Bellicum Pharmaceuticals Strategic initiatives
Table 80. Creagene Profiles
Table 81. Creagene Dendritic Cell Cancer Vaccine Product Introduction
Table 82. Creagene Dendritic Cell Cancer Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 83. Creagene Strategic initiatives
Table 84. DanDrit Biotech Profiles
Table 85. DanDrit Biotech Dendritic Cell Cancer Vaccine Product Introduction
Table 86. DanDrit Biotech Dendritic Cell Cancer Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 87. DanDrit Biotech Strategic initiatives
Table 88. DCPrime Profiles
Table 89. DCPrime Dendritic Cell Cancer Vaccine Product Introduction
Table 90. DCPrime Dendritic Cell Cancer Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 91. DCPrime Strategic initiatives
Table 92. Sanpower Corporation (Dendreon) Profiles
Table 93. Sanpower Corporation (Dendreon) Dendritic Cell Cancer Vaccine Product Introduction
Table 94. Sanpower Corporation (Dendreon) Dendritic Cell Cancer Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 95. Sanpower Corporation (Dendreon) Strategic initiatives
Table 97. Elios Therapeutics Profiles
Table 98. Elios Therapeutics Dendritic Cell Cancer Vaccine Product Introduction
Table 99. Elios Therapeutics Dendritic Cell Cancer Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 100. Elios Therapeutics Strategic initiatives
Table 101. Immunicum Profiles
Table 102. Immunicum Dendritic Cell Cancer Vaccine Product Introduction
Table 103. Immunicum Dendritic Cell Cancer Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 104. Immunicum Strategic initiatives
Table 105. Kiromic Profiles
Table 106. Kiromic Dendritic Cell Cancer Vaccine Product Introduction
Table 107. Kiromic Dendritic Cell Cancer Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 108. Kiromic Strategic initiatives
Table 109. Merck Profiles
Table 110. Merck Dendritic Cell Cancer Vaccine Product Introduction
Table 111. Merck Dendritic Cell Cancer Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 112. Merck Strategic initiatives
Table 113. Northwest Biotherapeutics Profiles
Table 114. Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Product Introduction
Table 115. Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 116. Northwest Biotherapeutics Strategic initiatives
Table 117. Glaxo Smith Kline Profiles
Table 118. Glaxo Smith Kline Dendritic Cell Cancer Vaccine Product Introduction
Table 119. Glaxo Smith Kline Dendritic Cell Cancer Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 120. Glaxo Smith Kline Strategic initiatives
Table 121. ImmunoCellular Profiles
Table 122. ImmunoCellular Dendritic Cell Cancer Vaccine Product Introduction
Table 123. ImmunoCellular Dendritic Cell Cancer Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 124. ImmunoCellular Strategic initiatives
Table 125. Tella Profiles
Table 126. Tella Dendritic Cell Cancer Vaccine Product Introduction
Table 127. Tella Dendritic Cell Cancer Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 128. Tella Strategic initiatives
Table 129. Vaxil Bio Profiles
Table 130. Vaxil Bio Dendritic Cell Cancer Vaccine Product Introduction
Table 131. Vaxil Bio Dendritic Cell Cancer Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 132. Vaxil Bio Strategic initiatives
Table 133. Medigene Profiles
Table 134. Medigene Dendritic Cell Cancer Vaccine Product Introduction
Table 135. Medigene Dendritic Cell Cancer Vaccine Production (Unit), Revenue (Million USD) (2018-2022)
Table 136. Medigene Strategic initiatives